Toshiaki Takizawa
Tokyo Research Laboratories
Pharmaceutical Division
Kowa Company
Ltd., Higashi-murayama
Japan
Name/email consistency: high
- Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin content in protease-activated receptor 2-deficient mice. Takizawa, T., Tamiya, M., Hara, T., Matsumoto, J., Saito, N., Kanke, T., Kawagoe, J., Hattori, Y. J. Pharmacol. Sci. (2005)
- Effect of antiallergic drugs on interleukin 5-induced eosinophil infiltration of rat airways. Takizawa, T., Kawada, N., Tanaka, H., Nagai, H. Biol. Pharm. Bull. (2002)
- VUF-K-8788, a periphery-selective histamine H1 antagonist with anti-pruritic activities. Takizawa, T., Matsumoto, J., Tohma, T., Kanke, T., Wada, Y., Nagao, M., Inagaki, N., Nagai, H., Zhang, M.Q., Timmerman, H. Jpn. J. Pharmacol. (2001)
- Effects of a new antiallergic drug, VUF-K-8788, on infiltration of lung parenchyma by eosinophils in guinea pigs and eosinophil-adhesion to human umbilical vein endothelial cells (HUVEC). Takizawa, T., Watanabe, C., Saiki, I., Wada, Y., Tohma, T., Nagai, H. Biol. Pharm. Bull. (2001)